Rapport Therapeutics, INC Form 4 insider transactions

Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 51,499 shares of common stock on August 10, 2026.

Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 2,210 shares of common stock on July 27, 2026.

Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 8,210 shares of common stock on July 14, 2026.

Rapport Therapeutics COO Cheryl Gault sold a total of 9,900 shares of common stock across multiple transactions on June 30, 2026, pursuant to a Rule 10b5-1 trading plan.

Rapport Therapeutics CEO Abraham Ceesay sold a significant number of shares under pre-arranged trading plans.

Director John Maraganore was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Director Robert J. Perez was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Director Steven M. Paul was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Director Paul M. Silva was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Director James Healy was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Director Reid M. Huber was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Director Wendy B. Young was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Director Ramiro Sanchez was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Third Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. (RAPP) at a weighted average price of $40.047.

Third Rock Ventures V, L.P. sold 133,618 shares of Rapport Therapeutics, Inc. (RAPP) at a weighted average price of $40.24 per share.

Third Rock Ventures V, L.P. and Third Rock Ventures VI, L.P. reported transactions involving the sale of Rapport Therapeutics, Inc. common stock.

Third Rock Ventures V, L.P. sold 426,005 shares of Rapport Therapeutics, Inc. (RAPP) at a weighted average price of $40.317.

Chief Development Officer Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics common stock.

Rapport Therapeutics Chief Development Officer, Yeleswaram Krishnaswamy, reported the sale of company stock totaling over 20,000 shares across multiple transactions.

Rapport Therapeutics, Inc. executive Yeleswaram Krishnaswamy reports a transaction involving common stock under a pre-arranged trading plan.

Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, sold 10,000 shares of common stock for approximately $280,000 through a pre-arranged trading plan.

Rapport Therapeutics' Chief Development Officer, Yeleswaram Krishnaswamy, sold 10,115 shares of common stock for approximately $30 per share under a pre-arranged 10b5-1 trading plan.

Rapport Therapeutics CEO Abraham Ceesay executed pre-planned sales of over 10,000 shares of common stock totaling approximately $320,000 through Rule 10b5-1 trading plans.

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock and exercised options for 6,000 shares under a pre-arranged trading plan.

Rapport Therapeutics' Chief Medical Officer, Jeffrey Sevigny, was granted 130,000 stock options with an exercise price of $27.75, vesting over four years.

Rapport Therapeutics, Inc. CEO Abraham Ceesay reported the acquisition of 428,000 stock options with an exercise price of $27.75.

Rapport Therapeutics' Chief Financial Officer, Troy A. Ignelzi, was granted 148,000 stock options with an exercise price of $27.75.

Rapport Therapeutics' Chief Development Officer, Krishnaswamy Yeleswaram, was granted 120,000 stock options with an exercise price of $27.75.

Rapport Therapeutics' Chief Scientific Officer, David Bredt, was granted 103,000 stock options with an exercise price of $27.75.

Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, was granted 132,000 stock options with an exercise price of $27.75.